• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 SYS PED.W/SA20 A.BURRHOLE RES; HYDROCEPHALUS MANAGEMENT,

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 SYS PED.W/SA20 A.BURRHOLE RES; HYDROCEPHALUS MANAGEMENT, Back to Search Results
Model Number FX448T
Medical Device Problem Code Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 09/23/2020
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The product for investigation has not yet reached us.When additional informations are provided a follow up will be submitted.
 
Event or Problem Description
It was reported that there was a problem with a progav 2.0 shuntsystem.The shuntsystem is blocked.Patient informations: date of implantation: (b)(6) 2017, date of removal: (b)(6) 2020, age: (b)(6), height cm: unknown, weight kg: 15, gender: unknown.
 
Additional Manufacturer Narrative
Investigation was done on 11/11/2020.Visual inspection: the following observations were made during the visual inspection: - no abnormalities were detected.Permeability test: the test showed that the progav 2.0 is permeable.Adjustability test: the progav 2.0 was found to be adjustable to all pressure settings.Braking force and brake function test: the braking force of the progav 2.0 was within the specified tolerance and the brake function operated as expected.Internal inspection of product: in order to verify whether the investigated valve was compromised by the known risks of hydrocephalus therapy, e.G.By a build-up of natural substances (protein, blood, or tissue particles) in the cerebrospinal fluid, we have dismantled the valve.After dismantling of the valve, some deposits were found in progav 2.0.Results: based on our investigation, we are not able to substantiate the claim of "blockage".However, we assume that the clearly deposits found within the valve may have temporarily caused the functional impairment.Deposits caused by natural substances in the cerebrospinal fluid, such as protein, blood or tissue particles, are among the known and unavoidable risks and side effects of hydrocephalus therapy.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.From our point of view, no further regulatory actions are required.
 
Event or Problem Description
The product was received on 11/06/2020 for investigation.Only the progav 2.0 valve was send in.The investigation could be performed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV 2.0 SYS PED.W/SA20 A.BURRHOLE RES
Common Device Name
HYDROCEPHALUS MANAGEMENT,
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
MDR Report Key10743676
Report Number3004721439-2020-00229
Device Sequence Number3312546
Product Code JXG
UDI-Device Identifier04041906137748
UDI-Public04041906137748
Combination Product (Y/N)N
Initial Reporter CountrySP
PMA/510(K) Number
K161853
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2017
Device Explanted Year2020
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source company representative,health
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 12/07/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date07/02/2022
Device Model NumberFX448T
Device Catalogue NumberFX448T
Device Lot Number20034385
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/06/2020
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 10/14/2020
Supplement Date Received by Manufacturer11/11/2020
Initial Report FDA Received Date10/27/2020
Supplement Report FDA Received Date12/09/2020
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age3 YR
Patient Weight15
-
-